Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural and functional insights into the B30.2/SPRY domain.

Jae-Sung Woo1, Joon-Hyuk Imm, Chang-Ki Min

  • 1Division of Molecular and Life Sciences, Department of Life Sciences, Center for Biomolecular Recognition, Pohang University of Science and Technology, Pohang, Kyungbuk, Korea.

The EMBO Journal
|February 25, 2006
PubMed
Summary

The B30.2/SPRY domain

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same author

Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone.

Future oncology (London, England)·2026
Same author

Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.

Blood research·2026
Same author

Cost-Effectiveness of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Aged 65 to 69 Years (CAREMM-2110 Study).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

The New England journal of medicine·2026
Same author

Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.

Clinical lymphoma, myeloma & leukemia·2026

Area of Science:

  • Structural biology
  • Molecular and cellular biology
  • Protein interactions

Background:

  • The B30.2/SPRY domain is found in ~700 eukaryotic proteins, including TRIM5alpha and Pyrin.
  • Its specific functional role and ligand-binding capabilities were previously unclear.

Purpose of the Study:

  • To elucidate the structure and function of the B30.2/SPRY domain.
  • To identify the ligand-binding site and understand its role in protein interactions.

Main Methods:

  • X-ray crystallography to determine the structure of GUSTAVUS SPRY-SOCS box protein with Elongins B and C.
  • Biochemical assays to identify and characterize protein-RNA interactions.

Main Results:

  • The crystal structure revealed a distorted beta-sandwich core for the B30.2/SPRY domain.

Related Experiment Videos

  • A specific surface was identified as the binding site for RNA helicase VASA (Kd = 40 nM).
  • This surface corresponds to regions involved in HIV-1 restriction (TRIM5alpha) and familial Mediterranean fever (Pyrin).

    • Conclusions:

    • The identified surface on the B30.2/SPRY domain acts as a ligand-binding site.
    • Variability in amino acids suggests these domains bind specific partner proteins, not consensus motifs.
    • This finding advances understanding of B30.2/SPRY domain function in diverse biological processes.